(Toronto, Ontario) – Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a clinical stage immunooncology company developing innovative drug candidates for the prevention and treatment of cancer, will be presenting on February 14, 2017 at the BIO CEO & Investor Conference, The Waldorf Astoria, New York, New York.
- 0 Comments
- FY2017